<DOC>
	<DOC>NCT02484872</DOC>
	<brief_summary>Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.</brief_summary>
	<brief_title>Has Inflammation a Significant Implication in Lung Cancer Evolution?</brief_title>
	<detailed_description>Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Lung neoplasms irrespective of stage, histology Previously treated lung neoplasms A history of prior malignant tumour, except nonmelanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year diseasefree interval)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Glasgow score</keyword>
	<keyword>Intensive Care Unit</keyword>
	<keyword>Emergency</keyword>
</DOC>